Strengthening Partnership Merck, Siemens to Accelerate Digital Transformation in Life Science Industry

Source: Press release Merck 2 min Reading Time

Related Vendors

Under a MOU signed between Merck and Siemens, both the companies will extend their partnership in order to accelerate digital transformation in the life science industry. The MOU focuses on delivering integrated software solutions, systems and consumables that harness automation, data and AI to connect drug discovery, development, and manufacturing.

The collaboration will focus on digital-first solutions that close workflow gaps in drug discovery and biomanufacturing by integrating Merck’s software-as-a-service products with Siemens’ digital ecosystem. (Source:  Merck KGaA)
The collaboration will focus on digital-first solutions that close workflow gaps in drug discovery and biomanufacturing by integrating Merck’s software-as-a-service products with Siemens’ digital ecosystem.
(Source: Merck KGaA)

Darmstadt/Germany – Merck and Siemens have recently signed a new Memorandum of Understanding (MOU) extending their strategic partnership to accelerate digital transformation in the life science industry. The MOU focuses on delivering integrated software solutions, systems and consumables that harness automation, data and AI to connect drug discovery, development, and manufacturing. The agreement marks the first joint use of technology acquired by Siemens as part of the Dotmatics acquisition that was completed in July 2025.

“Through this collaboration with Siemens, we are opening new possibilities for scientists to move faster from an idea in the lab to a therapy for patients,” said Jean-Charles Wirth, Member of the Executive Board and CEO Life Science, Merck. “By combining our strengths, we aim to change how science advances, unlocking new ways to accelerate scientific progress.”

“We are partnering with Merck to give scientists around the world the instruments to speed up the development of life-saving medication,” said Cedrik Neike, Member of the Managing Board at Siemens and CEO of Siemens Digital Industries. “Every few years the cost for developing a new drug is doubling. Data, AI and digitalization are key to break this paradigm. We are connecting every step of drug development through a digital backbone – so that data flows seamlessly, insights emerge faster, and medication reaches patients faster.”

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

The collaboration will focus on digital-first solutions that close workflow gaps in drug discovery and biomanufacturing by integrating Merck’s software-as-a-service (SaaS) products with Siemens’ digital ecosystem. Initial pilot projects include making Merck’s AI tools and digital applications available in Luma, Siemens' Dotmatics Scientific Intelligence Platform acquired as part of Dotmatics. This gives scientists a single environment that links product ordering with immediate access to the digital tools and insights they need to make faster, data-driven decisions.

Building on these projects, Siemens and Merck will pursue new joint projects and explore deeper integration over time. These initiatives include co-developing smarter data management tools and intuitive interfaces that make advanced processes easier for scientists to use. The partnership is also evaluating digital marketplaces that would give customers streamlined access to complementary technologies and services.

Together, Merck and Siemens see digital innovation as central to the future of life sciences. This partnership is designed to set a new standard for digital transformation, giving scientists and manufacturers the tools to deliver breakthroughs faster. It also builds on earlier MoUs between the two companies in smart manufacturing, reflecting a shared commitment to advancing innovation across the industry.

(ID:50571515)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent